TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Functional Magnetic Resonance Imaging (fMRI) Study of Nasal Strips in Nasal Congestion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with a self-rating of at least 3 to 8 for nasal congestion on the numerical rating scale~* Participants with a nasal congestion frequency score of 1, 2, 3 or 4.~Exclusion Criteria:~* Evidence of obstructive nasal polyps, nasal tract structural malformations, visible open sores, sunburn, irritation, eczema or chronic skin condition on the face or nose~* Use of any medications like nasal decongestant, alpha adrenergic drugs, glucocorticoids and any current treatment which in the opinion of the investigator will affect nasal congestion~* Known or suspected intolerance or hypersensitivity to the study materials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test nasal strip (Type: EXPERIMENTAL): Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
- Placebo nasal strip (Type: PLACEBO_COMPARATOR): Placebo nasal strip to be applied for up to two hours in either of the first two scans only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Post menopausal women,~* Ages 35 or older,~* Frequent moderate to severe hot flushes,~* Qualifying general medical health~Exclusion Criteria:~* Disqualifying gynecological disorders,~* Disqualifying dermatological disorders,~* Disqualifying concurrent conditions

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo transdermal three 90 μL sprays (Type: PLACEBO_COMPARATOR): Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
- Placebo transdermal two 90 μL sprays (Type: PLACEBO_COMPARATOR): Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
- Placebo transdermal one 90 μL spray (Type: PLACEBO_COMPARATOR): Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
- Estradiol transdermal three 90 μL sprays (Type: ACTIVE_COMPARATOR): Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
- Estradiol transdermal two 90 μL sprays (Type: ACTIVE_COMPARATOR): Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
- Estradiol transdermal one 90 μL spray (Type: ACTIVE_COMPARATOR): Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-cutting Laser Therapy in the Treatment of Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 15 years or older of either gender and of any racial/ethnic group.~* Presence of clinically-evident facial acne.~* Subjects must be in generally good health.~* Subjects must be able and willing to comply with the requirements of the protocol.~* You must live within a reasonable driving distance of Ann Arbor, Michigan, and/or be able to attend all of the scheduled appointments during the study.~Exclusion Criteria:~* Oral retinoid (Accutane) use within 6 months of entry into the study.~* Systemic acne therapies (oral antibiotics) within 4 weeks of entry into the study.~* Topical acne therapies (retinoids, antibiotics) within 2 weeks of entry into the study.~* Microdermabrasion or superficial chemical peels at the sites to be treated within 2 months of entry into the study.~* Subjects with a history of dermabrasion or laser resurfacing at the sites to be treated.~* Use of topical lipid absorbing substances (Clinac AC) within 2 weeks of entry into the study.~* Non-compliant subjects.~* Subjects with a significant medical history or concurrent illness/condition which the investigator(s) feel is not safe for study participation.~* Subjects using alcohol-based topical solutions or exfoliating agents within 2 weeks of entry into the study.~* Subjects with a history of very frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections.~* History of keloid (excessive scar) formation for subjects undergoing biopsies.~* Pregnant or nursing females.~* Subjects with known allergy or hypersensitivity to topical photosensitizing agents.~* Subjects with known photosensitivity disorders felt by the investigators to preclude safe inclusion in the study.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laser Therapy (Type: EXPERIMENTAL): V-Beam laser, Candela Corp., 595 nm wavelength
- Control (Type: NO_INTERVENTION): Untreated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with type 1 or type 2 diabetes~* diabetic macular edema involving the foveal center with CRT \>300 μm measured by OCT~* at least 3 and maximum 9 monthly intravitreal injections of anti-VEGF~Exclusion Criteria:~* uncontrolled diabetes (blood glucose ≥ 250 mg/dL at any time~* previous IDI~* any condition precluding adequate fundus visualization~* uncontrolled glaucoma~* papillary excavation ≥ 0.7

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravitreal dexamethasone implant (Type: EXPERIMENTAL): All patients were included here and received one intravitreal dexamethasone implant 0.7mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clopidogrel Pharmacogenomics Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:• Currently taking clopidogrel 75 mg/day and aspirin (minimum 81 mg/day) with an indication for chronic dual antiplatelet therapy (\>90 days)~* No evidence of acute coronary syndrome within 30 days of enrollment, defined by elevation of Troponin I above the upper limit of normal~* Coronary atherosclerosis documented on previous coronary angiogram~* No known contraindications to combination therapy with aspirin and clopidogrel~* Prognosis for survival greater than one year based on physician's assessment~* Able to attend all scheduled visits.~* Access to phone~* Subject is a female with a negative urine or serum pregnancy test or post-menopausal for at least 1 year prior to randomization. Females of childbearing potential must be practicing adequate birth control to be eligible. It is the Investigator's responsibility for determining whether the Subject has adequate birth control for study participation~Exclusion Criteria:• Recent acute coronary syndrome (\<30 days)~* Recent hospitalization or physician visit for bleeding disorder(\<90 days) or history of chronic blood loss~* Recent blood transfusion (\<90 days)~* Any contraindication to aspirin or clopidogrel therapy~* Acute Febrile illness at the time of enrollment~* Subject is pregnant or lactating or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 75 mg clopidogrel (Type: ACTIVE_COMPARATOR): None
- 150 mg clopidogrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women above 18 years of age~* Less than 12 weeks of gestation.~* Pregnancy is confirmed by pregnancy test or ultrasound scan.~* missed abortion~* Normal general and gynecological examination.~* The size of the uterus on pelvic examination was compatible with the estimated duration of pregnancy~Exclusion Criteria:~* Hemodynamically unstable.~* Suspected sepsis with temperature 38 °C.~* Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism, respiratory illnesses, recent liver disease or pruritus of pregnancy.~* Presence of intrauterine contraceptive device (IUCD).~* Suspect or proven ectopic pregnancy.~* Failed medical or surgical evacuation before presentation.~* Known allergy to misoprostol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- sublingual misoprostol (Type: EXPERIMENTAL): Group A (100 patients): will be treated with sublingual misoprostol
- vaginal misoprostol (Type: ACTIVE_COMPARATOR): Group B (100 patients): will be treated with vaginal misoprostol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing cataract surgery~Exclusion Criteria:~* Uncontrolled ocular disease in cataract surgery eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adults 2-65 years of age (inclusive) of either gender.~* Diagnosis of VL confirmed by spleen or bone marrow aspirate.~* Clinical signs and symptoms compatible with VL.~* Biochemical and haematological test values as follows:~* Haemoglobin \> 3.5g/100mL~* White blood cell count \> 0.75 x109/L~* Platelet count \> 40 x 109/L~* AST, ALT and alkaline phosphatase \< 5 times upper normal limit~* Prothrombin time \< 4 seconds above control~* Serum creatinine levels - 1.5 times upper normal limit~* Serum potassium levels within normal limits~* HIV negative.~Exclusion Criteria:~* A history of intercurrent or concurrent diseases (e.g. chronic alcohol consumption or drug addiction; renal, hepatic, cardiovascular or CNS disease; diabetes; tuberculosis; other infectious or major psychiatric diseases) that may introduce variables that affect the outcome of the study.~* Any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up.~* Proteinuria (\> 2+).~* A history of allergy or hypersensitivity to amphotericin B~* Previous treatment for VL within two weeks of enrollment into the study.~* Prior treatment failures with amphotericin B.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): a single dose of 10 mg/kg of liposomal amphotericin B
- 2 (Type: ACTIVE_COMPARATOR): amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is an ambulatory, community-dwelling male or nonpregnant female and is at least 18 years old at the Screening Visit. Lactating females must agree not to breastfeed.~* Patient has a diagnosis of GERD and reports experiencing GERD symptoms (heartburn or regurgitation) on ≥ 4 days per week during the 8 weeks before the Screening Visit while taking standard QD PPI therapy.~Exclusion Criteria:~* Patient may not meet any of the excluded conditions specified in the protocol~* Patient has any alarm symptoms including but not limited to GI bleeding, anemia, vomiting, dysphagia, or unexpected weight loss any time during the Screening or Pretreatment Periods~* Patient has a history of clinically significant hypersensitivity or allergies to any of the excipients contained in the study medication (active or placebo).~NOTE: Additional inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Matching placebo twice daily
- 500 mg IW-3718 (Type: EXPERIMENTAL): 500 mg IW-3718 twice daily
- 1000 mg IW-3718 (Type: EXPERIMENTAL): 1000 mg IW-3718 twice daily
- 1500 mg IW-3718 (Type: EXPERIMENTAL): 1500 mg IW-3718 twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug in Patients With Osteoarthritis (0663-073)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with osteoarthritis of the hip or knee who use current approved medication (nonsteroidal anti-inflammatory drugs (NSAIDs)) or tylenol to treat the symptoms of their osteoarthritis. Patients taking NSAIDs are required to discontinue using these drugs and their symptoms must become worse.~Exclusion Criteria:~* Patients with certain medical conditions may not be allowed to participate. These conditions will be reviewed with the study physician.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Man or woman aged 18 years or greater, recipient of a primary liver transplant from a deceased donor with whole or split liver~Key Exclusion Criteria:~* Patient recipient of multiple solid organ or islet cell tissue transplants, or have previously received an organ or tissue transplant~* Recipient of a liver from a living donor or cadaveric non heart beating donor~* ABO incompatible transplant graft~* Transplantation following autoimmune liver hepatitis, primitive sclerosing cholangitis or primitive biliary cirrhosis~* Estimated glomerular filtration rate ≤ 30ml/min at selection~* History of malignancy within the 5 past years, other than non-metastatic basal or squamous cell carcinoma and hepatocellular carcinoma~* Alpha-foeto-protein \> 1000 ng/ml (only in case of hepatocellular carcinoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus (Type: ACTIVE_COMPARATOR): From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
- Everolimus (RAD001) (Type: EXPERIMENTAL): From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids.~From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is scheduled to undergo lower abdominal surgery under a short general anesthesia of less than 2 hours~2. Subject's American Society of Anesthesiologists physical status is I-II.~3. The subject's parent/legally authorized guardian has given written informed consent to participate.~Exclusion Criteria:~1. Subject has a diagnosis of renal or liver failure.~2. Subject has a diagnosis of Insulin dependent diabetes.~3. Subject is allergy and contraindication to butorphanol or NSAIDs.~4. Subject has a history of chronic pain, a history of alcohol or opioid abuse, pre-existing therapy with opioids, intake of any analgesic drug within 48 hours before surgery.~5. Subject has any contraindication for the use of patient-controlled analgesia (PCA).~6. Subject is pregnant or breast-feeding.~7. Subject is obese (body mass index \>30kg/m\^2).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
- Butorphanol (Type: ACTIVE_COMPARATOR): Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
- Flurbiprofen axetilⅠ (Type: ACTIVE_COMPARATOR): Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
- Flurbiprofen axetilⅡ (Type: ACTIVE_COMPARATOR): Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
- Butorphanol-Flurbiprofen axetil (Type: ACTIVE_COMPARATOR): A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
- Sufentanil (Type: SHAM_COMPARATOR): Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who were treated with fondaparinux pre-, peri- and/or postpartum for more than 7 days for VTE prophylaxis or treatment, especially those with a history of abortion, and/or stillbirth, VTE, severe fetal and maternal complications during pregnancy, severe inherited or acquired thrombophilias, long-term anticoagulation (e. g. patients with mechanical heart valves) and/or intolerance to heparins or heparinoids or heparin-induced thrombocytopenia (HIT)~Exclusion Criteria:~* Patients who were treated with fondaparinux for less than 7 days~* Patient who were treated with fondaparinux only postpartum

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fondaparinux prescribed subjects (Type: None): fondaparinux prescribed subjets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete